PTC Therapeutics, a US pharmaceutical company, plans to expand its European headquarters in Dublin to 40 staff.
The Dublin site of the company is responsible for finance, quality assurance, legal and a raft of other back office roles.
"We currently employ 30 people in the Dublin office and this will increase to a total of 40 sustainable jobs in this office within a short period of time," said Adrian Haigh, who heads up the company's international operations.
PTC focuses on the discovery and commercialisation of novel medicines. It has been working on the development of a drug called Translarna for almost 20 years. The drug is the only protein restoration therapy for the treatment of nonsense mutation Duchenne Muscular Dystrophy – a genetic disorder characterised by progressive muscle degeneration.
“Discovering drugs that alter the course of the diseases and hopefully change the lives of these patients gives our work incredible purpose. So, it is an exciting time to be part of this rapidly expanding company that is dedicated to research and development of unique treatments to improve the quality of life for people with rare diseases,” Mr Haigh added.
